Is it justified to offer intrauterine infusion of autologous PRP in women with repeated implantation failure?
Human Reproduction · 01.05.2025 · 40 (5) · 771-784
DOI: 10.1093/humrep/deaf014 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Human Reproduction, online erschienen am 17.03.2025. Verfasst von Evangelia T Katsika und 3 weiteren Autor:innen. Beteiligte Einrichtung: Unit for Human Reproduction, 1st Department of Obstetrics and Gynecology, Medical School, Aristotle University of Thessaloniki, Thessaloniki, Greece. Hauptthemen laut MEDLINE: Platelet-Rich Plasma, Embryo Implantation, Infertility, Female. Die Arbeit wurde bisher 10-mal zitiert (Crossref) und nennt 53 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0).
Abstract (Originalsprache)
In recent years, an increased interest in the efficacy of intrauterine infusion of autologous platelet-rich plasma (PRP) in women with repeated implantation failure (RIF) has resulted in the publication of 13 randomized controlled trials (RCTs) and 11 meta-analyses. Although these meta-analyses support an increase in pregnancy rates after intrauterine infusion of autologous PRP, the low quality of the available original clinical studies along with concerns regarding their trustworthiness seriously questions their internal validity and does not allow for definitive conclusions to be drawn. In addition, the variability in the definition of RIF used in the individual studies limits their external validity, renders the pooling of the results problematic, and, overall, complicates the extrapolation of the results published. The variability in the definition of RIF has been recently addressed by the ESHRE, which published an evidence-based definition of RIF to facilitate the evaluation of interventions in these patients. Taking into consideration this definition, which identifies a real clinical problem, evaluation of intrauterine infusion of PRP in the published literature has not so far been performed explicitly in patients with RIF. The potential of intrauterine infusion of autologous PRP to improve outcomes for women with RIF remains an important area of research in ART. However, the current evidence is insufficient to inform clinical practice, highlighting the need for well-designed studies to provide clearer guidance.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Unit for Human Reproduction, 1st Department of Obstetrics and Gynecology, Medical School, Aristotle University of Thessaloniki, Thessaloniki, Greece.
- Centre for Big Data Research in Health, Faculty of Medicine & Health, University of New South Wales, Sydney, NSW, Australia.
ORCID-Profile: Evangelia T Katsika, Christos A Venetis, Julia K Bosdou, Efstratios M Kolibianakis
Zitieren
APA
Katsika, E. T., Venetis, C. A., Bosdou, J. K., & Kolibianakis, E. M. (2025). Is it justified to offer intrauterine infusion of autologous PRP in women with repeated implantation failure?. Human Reproduction, 40(5), 771-784. https://doi.org/10.1093/humrep/deaf014
Vancouver
Katsika ET, Venetis CA, Bosdou JK, Kolibianakis EM. Is it justified to offer intrauterine infusion of autologous PRP in women with repeated implantation failure?. Human Reproduction. 2025;40(5):771-784. doi:10.1093/humrep/deaf014
BibTeX
@article{Katsika2025,
author = {Katsika, Evangelia T and Venetis, Christos A and Bosdou, Julia K and Kolibianakis, Efstratios M},
title = {Is it justified to offer intrauterine infusion of autologous PRP in women with repeated implantation failure?},
journal = {Human Reproduction},
year = {2025},
volume = {40},
number = {5},
pages = {771--784},
doi = {10.1093/humrep/deaf014}
}
EUVIMED